Portada Simposios - Supplements - Haematologica

XLII Reunión Nacional de la AEHH y XVI Congreso de la SETH. Programa educacional
37
9. Sarris A. Prognostic factors in early-stage Hodgkin’s disease. J Clin Oncol
1997; 15: 411-412.
10. Hasenclever D, Diehl V, for the International Prognostic Factors Project
on Advanced Hodgkin’s Disease. A prognostic score for advanced
Hodgkin’s disease. N Engl J Med 1998; 339: 1506-1514.
11. Advani RH, Horning S. Treatment of early-stage Hodgkin’s disease. Semin
Hematol 1999; 36: 270-281.
12. Santoro A, Bonfante V, Viviani S et al. Subtotal nodal versus involved
field irradiation after 4 cycles of ABVD in early stage Hodgkin’s disease.
Proc ASCO 1996; 15: 415.
13. Rueda A, Alba E, Ribelles N et al. Six cycles of ABVD in the treatment
of stage I and II Hodgkin’s lymphoma: a pilot study. J Clin Oncol 1997;
15: 1118-1122.
14. Engert A, Wolf J, Diehl V. Treatment of advanced Hodgkin’s lymphoma:
standard and experimental approaches. Semin Hematol 1999; 36:
282-289.
15. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced
Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with
ABVD. N Engl J Med 1992; 327: 1478-1484.
16. Connors JM, Klimo P, Adams G et al. Treatment of advanced Hodgkin’s
disease with chemotherapy-Comparison of MOPP/ABV hybrid regimen
with alternating courses of MOPP and ABVD: a report of the National
Cancer Institute of Canada clinical trials groups. J Clin Oncol 1997; 15:
1638-1645.
17. Diehl V, Loeffler M, Pfreundschuh M et al. Further chemotherapy versus
low-dose involved-field radiotherapy as consolidation of complete remission
after six cycles of alternating chemotherapy in patients with advanced
Hodgkin’s disease. Ann Oncol 1995; 6: 901-910.
18. Montoto S, Camós M, López-Guillermo A et al. Hybrid chemotherapy
consisting of cyclophosphamide, vincristine, procarbazine, prednisone,
doxorubicin, bleomycin, and vinblastibe (C-MOPP/ABV) as first-line
treatment for patients with advanced Hodgkin’s disease. Cancer 2000;
88: 2142-2148.
19. Duggan D, Petroni G, Johnson J et al. MOPP/ABV versus ABVD for advanced
Hodgkin’s disease - a preliminary report of CALGB 8952 (with
SWOG, ECOG, NCIC). Proc. ASCO 1997; 16: 12a.
20. Diehl V, Franklin J, Hasenclever D et al. BEACOPP, a new dose-escalated
and accelerated regimen, is at least as effective as COPP/ABVD in
patients with advanced-stage Hodgkin’s lymphoma: interim report
from a trial of the German Hodgkin’s lymphoma Study Group. J Clin
Oncol 1998; 16: 3810-21. [actualizado: Fourth Interim analysis. Proc.
VIIth Int. Conf. on Malignant Lymphomas, Lugano 1999 Ann Oncol
10 (Supl. 3): 22, 1999 (abstr. 022)].
21. Horning S, Williams J, Barlett NL et al. Assessment of the Stanford V regimen
and consolidative radiotherapy for bulky and advanced Hodgkin’s
disease: Eastern Cooperative Oncology Group pilot study E1492.
J Clin Oncol 2000; 18: 972-980.
22. Ng AK, Mauch PM. Radiation therapy in Hodgkin’s lymphoma. Semin
Hematol 1999; 36: 290-302.
23. Carde P. Should poor risk patients be sorted out for intensive treatments
Leuk Lymph 1995; 15 (Supl. 1): 31-40.
24. Laurence ADJ, Goldstone AH. High-dose therapy with hematopoietic
transplantation for Hodgkin’s lymphoma. Semin Hematol 1999; 36:
303-312.
25. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous
bone marrow transplantation in relapsed and resistant Hodgkin’s
disease: results of a BNLI randomized trial. Lancet 1993; 341:
1051-1060.
26. Van Leewen FE, Klokman WJ, Hagenbeek A et al. Second cancer risk
following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol
1994; 12: 312-325.
27. Van Leewen FE, Klokman WJ, van’t Veer MB et al. Long-term risk of second
malignancy in survivors of Hodgkin’s disease treated during adolescence
or young adulthood. J Clin Oncol 2000; 18: 487-497.
28. Swerdlow AJ, Barber JA, Vaughan Hudson G et al. risk od second malignancy
after Hodgkin’s disease in a collaborative British cohort: the
relation to age at treatment. J Clin Oncol 2000; 498-509.